 | • レポートコード：MRC2-11QY03028 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、114ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料はベッカー型筋ジストロフィー治療薬のグローバル市場について調査・分析したレポートです。種類別（ジビノスタット、アタルレン、エピカテキン、ARM-210、その他）市場規模、用途別（病院、診療所、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別ベッカー型筋ジストロフィー治療薬の競争状況、市場シェア ・世界のベッカー型筋ジストロフィー治療薬市場：種類別市場規模 2015年-2020年（ジビノスタット、アタルレン、エピカテキン、ARM-210、その他） ・世界のベッカー型筋ジストロフィー治療薬市場：種類別市場規模予測 2021年-2026年（ジビノスタット、アタルレン、エピカテキン、ARM-210、その他） ・世界のベッカー型筋ジストロフィー治療薬市場：用途別市場規模 2015年-2020年（病院、診療所、その他） ・世界のベッカー型筋ジストロフィー治療薬市場：用途別市場規模予測 2021年-2026年（病院、診療所、その他） ・北米のベッカー型筋ジストロフィー治療薬市場分析：米国、カナダ ・ヨーロッパのベッカー型筋ジストロフィー治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアのベッカー型筋ジストロフィー治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米のベッカー型筋ジストロフィー治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカのベッカー型筋ジストロフィー治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Italfarmaco SpA、Milo Biotechnology LLC、PTC Therapeutics Inc、ReveraGen BioPharma Inc、Sarepta Therapeutics Inc ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Becker Muscular Dystrophy Drug Market
The global Becker Muscular Dystrophy Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Becker Muscular Dystrophy Drug Scope and Market Size
Becker Muscular Dystrophy Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Becker Muscular Dystrophy Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Becker Muscular Dystrophy Drug market is segmented into
Givinostat
Ataluren
Epicatechin
ARM-210
Others
Segment by Application, the Becker Muscular Dystrophy Drug market is segmented into
Hospital
Clinic
Others
Regional and Country-level Analysis
The Becker Muscular Dystrophy Drug market is analysed and market size information is provided by regions (countries).
The key regions covered in the Becker Muscular Dystrophy Drug market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Becker Muscular Dystrophy Drug Market Share Analysis
Becker Muscular Dystrophy Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Becker Muscular Dystrophy Drug business, the date to enter into the Becker Muscular Dystrophy Drug market, Becker Muscular Dystrophy Drug product introduction, recent developments, etc.
The major vendors covered:
Italfarmaco SpA
Milo Biotechnology LLC
PTC Therapeutics Inc
ReveraGen BioPharma Inc
Sarepta Therapeutics Inc
…
1 Study Coverage
1.1 Becker Muscular Dystrophy Drug Product Introduction
1.2 Market Segments
1.3 Key Becker Muscular Dystrophy Drug Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Becker Muscular Dystrophy Drug Market Size Growth Rate by Type
1.4.2 Givinostat
1.4.3 Ataluren
1.4.4 Epicatechin
1.4.5 ARM-210
1.4.6 Others
1.5 Market by Application
1.5.1 Global Becker Muscular Dystrophy Drug Market Size Growth Rate by Application
1.5.2 Hospital
1.5.3 Clinic
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Becker Muscular Dystrophy Drug Market Size, Estimates and Forecasts
2.1.1 Global Becker Muscular Dystrophy Drug Revenue 2015-2026
2.1.2 Global Becker Muscular Dystrophy Drug Sales 2015-2026
2.2 Global Becker Muscular Dystrophy Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Becker Muscular Dystrophy Drug Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Becker Muscular Dystrophy Drug Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Becker Muscular Dystrophy Drug Competitor Landscape by Players
3.1 Becker Muscular Dystrophy Drug Sales by Manufacturers
3.1.1 Becker Muscular Dystrophy Drug Sales by Manufacturers (2015-2020)
3.1.2 Becker Muscular Dystrophy Drug Sales Market Share by Manufacturers (2015-2020)
3.2 Becker Muscular Dystrophy Drug Revenue by Manufacturers
3.2.1 Becker Muscular Dystrophy Drug Revenue by Manufacturers (2015-2020)
3.2.2 Becker Muscular Dystrophy Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Becker Muscular Dystrophy Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Becker Muscular Dystrophy Drug Revenue in 2019
3.2.5 Global Becker Muscular Dystrophy Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Becker Muscular Dystrophy Drug Price by Manufacturers
3.4 Becker Muscular Dystrophy Drug Manufacturing Base Distribution, Product Types
3.4.1 Becker Muscular Dystrophy Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Becker Muscular Dystrophy Drug Product Type
3.4.3 Date of International Manufacturers Enter into Becker Muscular Dystrophy Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Becker Muscular Dystrophy Drug Market Size by Type (2015-2020)
4.1.1 Global Becker Muscular Dystrophy Drug Sales by Type (2015-2020)
4.1.2 Global Becker Muscular Dystrophy Drug Revenue by Type (2015-2020)
4.1.3 Becker Muscular Dystrophy Drug Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Becker Muscular Dystrophy Drug Market Size Forecast by Type (2021-2026)
4.2.1 Global Becker Muscular Dystrophy Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Becker Muscular Dystrophy Drug Revenue Forecast by Type (2021-2026)
4.2.3 Becker Muscular Dystrophy Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Becker Muscular Dystrophy Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Becker Muscular Dystrophy Drug Market Size by Application (2015-2020)
5.1.1 Global Becker Muscular Dystrophy Drug Sales by Application (2015-2020)
5.1.2 Global Becker Muscular Dystrophy Drug Revenue by Application (2015-2020)
5.1.3 Becker Muscular Dystrophy Drug Price by Application (2015-2020)
5.2 Becker Muscular Dystrophy Drug Market Size Forecast by Application (2021-2026)
5.2.1 Global Becker Muscular Dystrophy Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Becker Muscular Dystrophy Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Becker Muscular Dystrophy Drug Price Forecast by Application (2021-2026)
6 North America
6.1 North America Becker Muscular Dystrophy Drug by Country
6.1.1 North America Becker Muscular Dystrophy Drug Sales by Country
6.1.2 North America Becker Muscular Dystrophy Drug Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Becker Muscular Dystrophy Drug Market Facts & Figures by Type
6.3 North America Becker Muscular Dystrophy Drug Market Facts & Figures by Application
7 Europe
7.1 Europe Becker Muscular Dystrophy Drug by Country
7.1.1 Europe Becker Muscular Dystrophy Drug Sales by Country
7.1.2 Europe Becker Muscular Dystrophy Drug Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Becker Muscular Dystrophy Drug Market Facts & Figures by Type
7.3 Europe Becker Muscular Dystrophy Drug Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Becker Muscular Dystrophy Drug by Region
8.1.1 Asia Pacific Becker Muscular Dystrophy Drug Sales by Region
8.1.2 Asia Pacific Becker Muscular Dystrophy Drug Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Becker Muscular Dystrophy Drug Market Facts & Figures by Type
8.3 Asia Pacific Becker Muscular Dystrophy Drug Market Facts & Figures by Application
9 Latin America
9.1 Latin America Becker Muscular Dystrophy Drug by Country
9.1.1 Latin America Becker Muscular Dystrophy Drug Sales by Country
9.1.2 Latin America Becker Muscular Dystrophy Drug Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Becker Muscular Dystrophy Drug Market Facts & Figures by Type
9.3 Central & South America Becker Muscular Dystrophy Drug Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Becker Muscular Dystrophy Drug by Country
10.1.1 Middle East and Africa Becker Muscular Dystrophy Drug Sales by Country
10.1.2 Middle East and Africa Becker Muscular Dystrophy Drug Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Becker Muscular Dystrophy Drug Market Facts & Figures by Type
10.3 Middle East and Africa Becker Muscular Dystrophy Drug Market Facts & Figures by Application
11 Company Profiles
11.1 Italfarmaco SpA
11.1.1 Italfarmaco SpA Corporation Information
11.1.2 Italfarmaco SpA Description and Business Overview
11.1.3 Italfarmaco SpA Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Italfarmaco SpA Becker Muscular Dystrophy Drug Products Offered
11.1.5 Italfarmaco SpA Related Developments
11.2 Milo Biotechnology LLC
11.2.1 Milo Biotechnology LLC Corporation Information
11.2.2 Milo Biotechnology LLC Description and Business Overview
11.2.3 Milo Biotechnology LLC Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Milo Biotechnology LLC Becker Muscular Dystrophy Drug Products Offered
11.2.5 Milo Biotechnology LLC Related Developments
11.3 PTC Therapeutics Inc
11.3.1 PTC Therapeutics Inc Corporation Information
11.3.2 PTC Therapeutics Inc Description and Business Overview
11.3.3 PTC Therapeutics Inc Sales, Revenue and Gross Margin (2015-2020)
11.3.4 PTC Therapeutics Inc Becker Muscular Dystrophy Drug Products Offered
11.3.5 PTC Therapeutics Inc Related Developments
11.4 ReveraGen BioPharma Inc
11.4.1 ReveraGen BioPharma Inc Corporation Information
11.4.2 ReveraGen BioPharma Inc Description and Business Overview
11.4.3 ReveraGen BioPharma Inc Sales, Revenue and Gross Margin (2015-2020)
11.4.4 ReveraGen BioPharma Inc Becker Muscular Dystrophy Drug Products Offered
11.4.5 ReveraGen BioPharma Inc Related Developments
11.5 Sarepta Therapeutics Inc
11.5.1 Sarepta Therapeutics Inc Corporation Information
11.5.2 Sarepta Therapeutics Inc Description and Business Overview
11.5.3 Sarepta Therapeutics Inc Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Sarepta Therapeutics Inc Becker Muscular Dystrophy Drug Products Offered
11.5.5 Sarepta Therapeutics Inc Related Developments
11.1 Italfarmaco SpA
11.1.1 Italfarmaco SpA Corporation Information
11.1.2 Italfarmaco SpA Description and Business Overview
11.1.3 Italfarmaco SpA Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Italfarmaco SpA Becker Muscular Dystrophy Drug Products Offered
11.1.5 Italfarmaco SpA Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Becker Muscular Dystrophy Drug Market Estimates and Projections by Region
12.1.1 Global Becker Muscular Dystrophy Drug Sales Forecast by Regions 2021-2026
12.1.2 Global Becker Muscular Dystrophy Drug Revenue Forecast by Regions 2021-2026
12.2 North America Becker Muscular Dystrophy Drug Market Size Forecast (2021-2026)
12.2.1 North America: Becker Muscular Dystrophy Drug Sales Forecast (2021-2026)
12.2.2 North America: Becker Muscular Dystrophy Drug Revenue Forecast (2021-2026)
12.2.3 North America: Becker Muscular Dystrophy Drug Market Size Forecast by Country (2021-2026)
12.3 Europe Becker Muscular Dystrophy Drug Market Size Forecast (2021-2026)
12.3.1 Europe: Becker Muscular Dystrophy Drug Sales Forecast (2021-2026)
12.3.2 Europe: Becker Muscular Dystrophy Drug Revenue Forecast (2021-2026)
12.3.3 Europe: Becker Muscular Dystrophy Drug Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Becker Muscular Dystrophy Drug Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Becker Muscular Dystrophy Drug Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Becker Muscular Dystrophy Drug Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Becker Muscular Dystrophy Drug Market Size Forecast by Region (2021-2026)
12.5 Latin America Becker Muscular Dystrophy Drug Market Size Forecast (2021-2026)
12.5.1 Latin America: Becker Muscular Dystrophy Drug Sales Forecast (2021-2026)
12.5.2 Latin America: Becker Muscular Dystrophy Drug Revenue Forecast (2021-2026)
12.5.3 Latin America: Becker Muscular Dystrophy Drug Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Becker Muscular Dystrophy Drug Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Becker Muscular Dystrophy Drug Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Becker Muscular Dystrophy Drug Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Becker Muscular Dystrophy Drug Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Becker Muscular Dystrophy Drug Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Becker Muscular Dystrophy Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Becker Muscular Dystrophy Drug Market Segments
Table 2. Ranking of Global Top Becker Muscular Dystrophy Drug Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Becker Muscular Dystrophy Drug Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of Givinostat
Table 5. Major Manufacturers of Ataluren
Table 6. Major Manufacturers of Epicatechin
Table 7. Major Manufacturers of ARM-210
Table 8. Major Manufacturers of Others
Table 9. Global Becker Muscular Dystrophy Drug Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 10. Global Becker Muscular Dystrophy Drug Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 11. Global Becker Muscular Dystrophy Drug Sales by Regions 2015-2020 (K Pcs)
Table 12. Global Becker Muscular Dystrophy Drug Sales Market Share by Regions (2015-2020)
Table 13. Global Becker Muscular Dystrophy Drug Revenue by Regions 2015-2020 (US$ Million)
Table 14. Global Becker Muscular Dystrophy Drug Sales by Manufacturers (2015-2020) (K Pcs)
Table 15. Global Becker Muscular Dystrophy Drug Sales Share by Manufacturers (2015-2020)
Table 16. Global Becker Muscular Dystrophy Drug Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 17. Global Becker Muscular Dystrophy Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Becker Muscular Dystrophy Drug as of 2019)
Table 18. Becker Muscular Dystrophy Drug Revenue by Manufacturers (2015-2020) (US$ Million)
Table 19. Becker Muscular Dystrophy Drug Revenue Share by Manufacturers (2015-2020)
Table 20. Key Manufacturers Becker Muscular Dystrophy Drug Price (2015-2020) (USD/Pcs)
Table 21. Becker Muscular Dystrophy Drug Manufacturers Manufacturing Base Distribution and Headquarters
Table 22. Manufacturers Becker Muscular Dystrophy Drug Product Type
Table 23. Date of International Manufacturers Enter into Becker Muscular Dystrophy Drug Market
Table 24. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 25. Global Becker Muscular Dystrophy Drug Sales by Type (2015-2020) (K Pcs)
Table 26. Global Becker Muscular Dystrophy Drug Sales Share by Type (2015-2020)
Table 27. Global Becker Muscular Dystrophy Drug Revenue by Type (2015-2020) (US$ Million)
Table 28. Global Becker Muscular Dystrophy Drug Revenue Share by Type (2015-2020)
Table 29. Becker Muscular Dystrophy Drug Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 30. Global Becker Muscular Dystrophy Drug Sales by Application (2015-2020) (K Pcs)
Table 31. Global Becker Muscular Dystrophy Drug Sales Share by Application (2015-2020)
Table 32. North America Becker Muscular Dystrophy Drug Sales by Country (2015-2020) (K Pcs)
Table 33. North America Becker Muscular Dystrophy Drug Sales Market Share by Country (2015-2020)
Table 34. North America Becker Muscular Dystrophy Drug Revenue by Country (2015-2020) (US$ Million)
Table 35. North America Becker Muscular Dystrophy Drug Revenue Market Share by Country (2015-2020)
Table 36. North America Becker Muscular Dystrophy Drug Sales by Type (2015-2020) (K Pcs)
Table 37. North America Becker Muscular Dystrophy Drug Sales Market Share by Type (2015-2020)
Table 38. North America Becker Muscular Dystrophy Drug Sales by Application (2015-2020) (K Pcs)
Table 39. North America Becker Muscular Dystrophy Drug Sales Market Share by Application (2015-2020)
Table 40. Europe Becker Muscular Dystrophy Drug Sales by Country (2015-2020) (K Pcs)
Table 41. Europe Becker Muscular Dystrophy Drug Sales Market Share by Country (2015-2020)
Table 42. Europe Becker Muscular Dystrophy Drug Revenue by Country (2015-2020) (US$ Million)
Table 43. Europe Becker Muscular Dystrophy Drug Revenue Market Share by Country (2015-2020)
Table 44. Europe Becker Muscular Dystrophy Drug Sales by Type (2015-2020) (K Pcs)
Table 45. Europe Becker Muscular Dystrophy Drug Sales Market Share by Type (2015-2020)
Table 46. Europe Becker Muscular Dystrophy Drug Sales by Application (2015-2020) (K Pcs)
Table 47. Europe Becker Muscular Dystrophy Drug Sales Market Share by Application (2015-2020)
Table 48. Asia Pacific Becker Muscular Dystrophy Drug Sales by Region (2015-2020) (K Pcs)
Table 49. Asia Pacific Becker Muscular Dystrophy Drug Sales Market Share by Region (2015-2020)
Table 50. Asia Pacific Becker Muscular Dystrophy Drug Revenue by Region (2015-2020) (US$ Million)
Table 51. Asia Pacific Becker Muscular Dystrophy Drug Revenue Market Share by Region (2015-2020)
Table 52. Asia Pacific Becker Muscular Dystrophy Drug Sales by Type (2015-2020) (K Pcs)
Table 53. Asia Pacific Becker Muscular Dystrophy Drug Sales Market Share by Type (2015-2020)
Table 54. Asia Pacific Becker Muscular Dystrophy Drug Sales by Application (2015-2020) (K Pcs)
Table 55. Asia Pacific Becker Muscular Dystrophy Drug Sales Market Share by Application (2015-2020)
Table 56. Latin America Becker Muscular Dystrophy Drug Sales by Country (2015-2020) (K Pcs)
Table 57. Latin America Becker Muscular Dystrophy Drug Sales Market Share by Country (2015-2020)
Table 58. Latin Americaa Becker Muscular Dystrophy Drug Revenue by Country (2015-2020) (US$ Million)
Table 59. Latin America Becker Muscular Dystrophy Drug Revenue Market Share by Country (2015-2020)
Table 60. Latin America Becker Muscular Dystrophy Drug Sales by Type (2015-2020) (K Pcs)
Table 61. Latin America Becker Muscular Dystrophy Drug Sales Market Share by Type (2015-2020)
Table 62. Latin America Becker Muscular Dystrophy Drug Sales by Application (2015-2020) (K Pcs)
Table 63. Latin America Becker Muscular Dystrophy Drug Sales Market Share by Application (2015-2020)
Table 64. Middle East and Africa Becker Muscular Dystrophy Drug Sales by Country (2015-2020) (K Pcs)
Table 65. Middle East and Africa Becker Muscular Dystrophy Drug Sales Market Share by Country (2015-2020)
Table 66. Middle East and Africa Becker Muscular Dystrophy Drug Revenue by Country (2015-2020) (US$ Million)
Table 67. Middle East and Africa Becker Muscular Dystrophy Drug Revenue Market Share by Country (2015-2020)
Table 68. Middle East and Africa Becker Muscular Dystrophy Drug Sales by Type (2015-2020) (K Pcs)
Table 69. Middle East and Africa Becker Muscular Dystrophy Drug Sales Market Share by Type (2015-2020)
Table 70. Middle East and Africa Becker Muscular Dystrophy Drug Sales by Application (2015-2020) (K Pcs)
Table 71. Middle East and Africa Becker Muscular Dystrophy Drug Sales Market Share by Application (2015-2020)
Table 72. Italfarmaco SpA Corporation Information
Table 73. Italfarmaco SpA Description and Major Businesses
Table 74. Italfarmaco SpA Becker Muscular Dystrophy Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 75. Italfarmaco SpA Product
Table 76. Italfarmaco SpA Recent Development
Table 77. Milo Biotechnology LLC Corporation Information
Table 78. Milo Biotechnology LLC Description and Major Businesses
Table 79. Milo Biotechnology LLC Becker Muscular Dystrophy Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 80. Milo Biotechnology LLC Product
Table 81. Milo Biotechnology LLC Recent Development
Table 82. PTC Therapeutics Inc Corporation Information
Table 83. PTC Therapeutics Inc Description and Major Businesses
Table 84. PTC Therapeutics Inc Becker Muscular Dystrophy Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 85. PTC Therapeutics Inc Product
Table 86. PTC Therapeutics Inc Recent Development
Table 87. ReveraGen BioPharma Inc Corporation Information
Table 88. ReveraGen BioPharma Inc Description and Major Businesses
Table 89. ReveraGen BioPharma Inc Becker Muscular Dystrophy Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 90. ReveraGen BioPharma Inc Product
Table 91. ReveraGen BioPharma Inc Recent Development
Table 92. Sarepta Therapeutics Inc Corporation Information
Table 93. Sarepta Therapeutics Inc Description and Major Businesses
Table 94. Sarepta Therapeutics Inc Becker Muscular Dystrophy Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 95. Sarepta Therapeutics Inc Product
Table 96. Sarepta Therapeutics Inc Recent Development
Table 97. Global Becker Muscular Dystrophy Drug Sales Forecast by Regions (2021-2026) (K Pcs)
Table 98. Global Becker Muscular Dystrophy Drug Sales Market Share Forecast by Regions (2021-2026)
Table 99. Global Becker Muscular Dystrophy Drug Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 100. Global Becker Muscular Dystrophy Drug Revenue Market Share Forecast by Regions (2021-2026)
Table 101. North America: Becker Muscular Dystrophy Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 102. North America: Becker Muscular Dystrophy Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 103. Europe: Becker Muscular Dystrophy Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 104. Europe: Becker Muscular Dystrophy Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 105. Asia Pacific: Becker Muscular Dystrophy Drug Sales Forecast by Region (2021-2026) (K Pcs)
Table 106. Asia Pacific: Becker Muscular Dystrophy Drug Revenue Forecast by Region (2021-2026) (US$ Million)
Table 107. Latin America: Becker Muscular Dystrophy Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 108. Latin America: Becker Muscular Dystrophy Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 109. Middle East and Africa: Becker Muscular Dystrophy Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 110. Middle East and Africa: Becker Muscular Dystrophy Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 111. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 112. Key Challenges
Table 113. Market Risks
Table 114. Main Points Interviewed from Key Becker Muscular Dystrophy Drug Players
Table 115. Becker Muscular Dystrophy Drug Customers List
Table 116. Becker Muscular Dystrophy Drug Distributors List
Table 117. Research Programs/Design for This Report
Table 118. Key Data Information from Secondary Sources
Table 119. Key Data Information from Primary Sources
List of Figures
Figure 1. Becker Muscular Dystrophy Drug Product Picture
Figure 2. Global Becker Muscular Dystrophy Drug Sales Market Share by Type in 2020 & 2026
Figure 3. Givinostat Product Picture
Figure 4. Ataluren Product Picture
Figure 5. Epicatechin Product Picture
Figure 6. ARM-210 Product Picture
Figure 7. Others Product Picture
Figure 8. Global Becker Muscular Dystrophy Drug Sales Market Share by Application in 2020 & 2026
Figure 9. Hospital
Figure 10. Clinic
Figure 11. Others
Figure 12. Becker Muscular Dystrophy Drug Report Years Considered
Figure 13. Global Becker Muscular Dystrophy Drug Market Size 2015-2026 (US$ Million)
Figure 14. Global Becker Muscular Dystrophy Drug Sales 2015-2026 (K Pcs)
Figure 15. Global Becker Muscular Dystrophy Drug Market Size Market Share by Region: 2020 Versus 2026
Figure 16. Global Becker Muscular Dystrophy Drug Sales Market Share by Region (2015-2020)
Figure 17. Global Becker Muscular Dystrophy Drug Sales Market Share by Region in 2019
Figure 18. Global Becker Muscular Dystrophy Drug Revenue Market Share by Region (2015-2020)
Figure 19. Global Becker Muscular Dystrophy Drug Revenue Market Share by Region in 2019
Figure 20. Global Becker Muscular Dystrophy Drug Sales Share by Manufacturer in 2019
Figure 21. The Top 10 and 5 Players Market Share by Becker Muscular Dystrophy Drug Revenue in 2019
Figure 22. Becker Muscular Dystrophy Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 23. Global Becker Muscular Dystrophy Drug Sales Market Share by Type (2015-2020)
Figure 24. Global Becker Muscular Dystrophy Drug Sales Market Share by Type in 2019
Figure 25. Global Becker Muscular Dystrophy Drug Revenue Market Share by Type (2015-2020)
Figure 26. Global Becker Muscular Dystrophy Drug Revenue Market Share by Type in 2019
Figure 27. Global Becker Muscular Dystrophy Drug Market Share by Price Range (2015-2020)
Figure 28. Global Becker Muscular Dystrophy Drug Sales Market Share by Application (2015-2020)
Figure 29. Global Becker Muscular Dystrophy Drug Sales Market Share by Application in 2019
Figure 30. Global Becker Muscular Dystrophy Drug Revenue Market Share by Application (2015-2020)
Figure 31. Global Becker Muscular Dystrophy Drug Revenue Market Share by Application in 2019
Figure 32. North America Becker Muscular Dystrophy Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 33. North America Becker Muscular Dystrophy Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 34. North America Becker Muscular Dystrophy Drug Sales Market Share by Country in 2019
Figure 35. North America Becker Muscular Dystrophy Drug Revenue Market Share by Country in 2019
Figure 36. U.S. Becker Muscular Dystrophy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 37. U.S. Becker Muscular Dystrophy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 38. Canada Becker Muscular Dystrophy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 39. Canada Becker Muscular Dystrophy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 40. North America Becker Muscular Dystrophy Drug Market Share by Type in 2019
Figure 41. North America Becker Muscular Dystrophy Drug Market Share by Application in 2019
Figure 42. Europe Becker Muscular Dystrophy Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 43. Europe Becker Muscular Dystrophy Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 44. Europe Becker Muscular Dystrophy Drug Sales Market Share by Country in 2019
Figure 45. Europe Becker Muscular Dystrophy Drug Revenue Market Share by Country in 2019
Figure 46. Germany Becker Muscular Dystrophy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 47. Germany Becker Muscular Dystrophy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. France Becker Muscular Dystrophy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 49. France Becker Muscular Dystrophy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. U.K. Becker Muscular Dystrophy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 51. U.K. Becker Muscular Dystrophy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. Italy Becker Muscular Dystrophy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 53. Italy Becker Muscular Dystrophy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Russia Becker Muscular Dystrophy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 55. Russia Becker Muscular Dystrophy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 56. Europe Becker Muscular Dystrophy Drug Market Share by Type in 2019
Figure 57. Europe Becker Muscular Dystrophy Drug Market Share by Application in 2019
Figure 58. Asia Pacific Becker Muscular Dystrophy Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 59. Asia Pacific Becker Muscular Dystrophy Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 60. Asia Pacific Becker Muscular Dystrophy Drug Sales Market Share by Region in 2019
Figure 61. Asia Pacific Becker Muscular Dystrophy Drug Revenue Market Share by Region in 2019
Figure 62. China Becker Muscular Dystrophy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 63. China Becker Muscular Dystrophy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 64. Japan Becker Muscular Dystrophy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 65. Japan Becker Muscular Dystrophy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. South Korea Becker Muscular Dystrophy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 67. South Korea Becker Muscular Dystrophy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. India Becker Muscular Dystrophy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 69. India Becker Muscular Dystrophy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Australia Becker Muscular Dystrophy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 71. Australia Becker Muscular Dystrophy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Taiwan Becker Muscular Dystrophy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 73. Taiwan Becker Muscular Dystrophy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Indonesia Becker Muscular Dystrophy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 75. Indonesia Becker Muscular Dystrophy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Thailand Becker Muscular Dystrophy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 77. Thailand Becker Muscular Dystrophy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Malaysia Becker Muscular Dystrophy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 79. Malaysia Becker Muscular Dystrophy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Philippines Becker Muscular Dystrophy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 81. Philippines Becker Muscular Dystrophy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Vietnam Becker Muscular Dystrophy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 83. Vietnam Becker Muscular Dystrophy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 84. Asia Pacific Becker Muscular Dystrophy Drug Market Share by Type in 2019
Figure 85. Asia Pacific Becker Muscular Dystrophy Drug Market Share by Application in 2019
Figure 86. Latin America Becker Muscular Dystrophy Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 87. Latin America Becker Muscular Dystrophy Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 88. Latin America Becker Muscular Dystrophy Drug Sales Market Share by Country in 2019
Figure 89. Latin America Becker Muscular Dystrophy Drug Revenue Market Share by Country in 2019
Figure 90. Mexico Becker Muscular Dystrophy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 91. Mexico Becker Muscular Dystrophy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 92. Brazil Becker Muscular Dystrophy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 93. Brazil Becker Muscular Dystrophy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 94. Argentina Becker Muscular Dystrophy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 95. Argentina Becker Muscular Dystrophy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 96. Latin America Becker Muscular Dystrophy Drug Market Share by Type in 2019
Figure 97. Latin America Becker Muscular Dystrophy Drug Market Share by Application in 2019
Figure 98. Middle East and Africa Becker Muscular Dystrophy Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 99. Middle East and Africa Becker Muscular Dystrophy Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 100. Middle East and Africa Becker Muscular Dystrophy Drug Sales Market Share by Country in 2019
Figure 101. Middle East and Africa Becker Muscular Dystrophy Drug Revenue Market Share by Country in 2019
Figure 102. Turkey Becker Muscular Dystrophy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 103. Turkey Becker Muscular Dystrophy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 104. Saudi Arabia Becker Muscular Dystrophy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 105. Saudi Arabia Becker Muscular Dystrophy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 106. U.A.E Becker Muscular Dystrophy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 107. U.A.E Becker Muscular Dystrophy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 108. Middle East and Africa Becker Muscular Dystrophy Drug Market Share by Type in 2019
Figure 109. Middle East and Africa Becker Muscular Dystrophy Drug Market Share by Application in 2019
Figure 110. North America Becker Muscular Dystrophy Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 111. North America Becker Muscular Dystrophy Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 112. Europe Becker Muscular Dystrophy Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 113. Europe Becker Muscular Dystrophy Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 114. Asia Pacific Becker Muscular Dystrophy Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 115. Asia Pacific Becker Muscular Dystrophy Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 116. Latin America Becker Muscular Dystrophy Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 117. Latin America Becker Muscular Dystrophy Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 118. Middle East and Africa Becker Muscular Dystrophy Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 119. Middle East and Africa Becker Muscular Dystrophy Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 120. Porter's Five Forces Analysis
Figure 121. Channels of Distribution
Figure 122. Distributors Profiles
Figure 123. Bottom-up and Top-down Approaches for This Report
Figure 124. Data Triangulation
Figure 125. Key Executives Interviewed
デュシェンヌ型筋ジストロフィー薬の世界市場（～2026年） Duchenne muscular dystrophy is an X-linked disease, which generally affects the male population. It is characterized by progressive muscle degeneration and weakness. The disease is caused due to mutations in the dystrophin gene, which result in the lack of production of dystrophin (a protein essenti…- 筋緊張性ジストロフィー治療薬の世界市場（～2026年） Market Analysis and Insights: Global Myotonic Dystrophy Drug Market The global Myotonic Dystrophy Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Myotonic Dystrophy Drug Scope and Market Size Myotonic Dystrophy Dr…
- 脊髄性筋萎縮症の世界市場（～2026年） Market Analysis and Insights: Global Spinal Muscular Atrophy Market The global Spinal Muscular Atrophy market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Spinal Muscular Atrophy Scope and Market Size Spinal Muscular Atrop…
- 脊髄性筋萎縮症（SMA）治療の世界市場（～2026年） Spinal muscular atrophy (SMA) refers to a group of inherited diseases that affects the functioning of muscles because of deterioration. North America dominates the global market for SMA treatment due to the high prevalence of SMA and increased adoption of SMA treatment options in the region. Market …
- 遺伝性疾患薬の世界市場（～2026年） Market Analysis and Insights: Global Genetic Disorders Drug Market The global Genetic Disorders Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Genetic Disorders Drug Scope and Market Size Genetic Disorders Drug m…